Alkermes plc · NASDAQ:ALKS
Alkermes — 42nd Annual J.P. Morgan Healthcare Conference 2024
28 slides from Alkermes's conference presentation, January 2024
Slide 1: Alkermes 2024: Profitable, Pure-play Neuroscience Company
Alkermes 2024: Profitable, Pure-play Neuroscience Company Richard Pops Chief Executive Officer 42nd Annual J.P. Morgan Healthcare Conference January 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations with respect t
Slide 3: Alkermes 2024: Profitable, Pure-play Neuroscience Company
Alkermes 2024: Profitable, Pure-play Neuroscience Company >$1B commercial business driven primarily by 4 core products* Proven development capabilities with advancing neuroscience pipeline Positioned for sustained profitability and significant cash generation *Based on revenues from VIVITROL®, ARIST
Slide 4: 2023 Accomplishments Enabled Repositioning of Alkermes and Established Strong Foundation for Growth
2023 Accomplishments Enabled Repositioning of Alkermes and Established Strong Foundation for Growth Prevailed in Janssen arbitration; Raised 2023 financial expectations Successfully settled VIVITROL® patent litigation Generated ALKS 2680 initial clinical proof-of-concept data in patients with narcol
Slide 5: 2024 Strategic Priorities
2024 Strategic Priorities Driven by 4 core products Deliver strong commercial growth and profitability and streamlined operating structure Advance orexin 2 receptor agonist Initiate phase 2 program program Advance internal development candidates and explore Expand neuroscience pipeline external pipe
Slide 6: >$1B Commercial Business Primarily Driven by 4 Core Products
>$1B Commercial Business Primarily Driven by 4 Core Products
Slide 7: Topline Growth and Diversification Reflect Evolving Business
Topline Growth and Diversification Reflect Evolving Business $1,022 Key Product Revenues ($M) $893 $715 $574 FY'20 FY'21 FY'22 Q3'23 R12M † VIVITROL® ARISTADA®* VUMERITY®** LYBALVI® *Inclusive of ARISTADA INITIO® **Licensed product (royalty & manufacturing revenue) †R12M = Rolling Twelve Months 7 ©
Slide 8: LYBALVI: Oral Treatment Option for Schizophrenia and Bipolar I Disorder
LYBALVI®: Oral Treatment Option for Schizophrenia and Bipolar I Disorder • Once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity • Indicated for the treatment of: ◦ Schizophrenia in adults ◦ Bipolar I disorder in ad
Slide 9: LYBALVI Launch Growth Trends
LYBALVI® Launch Growth Trends Post-Launch Weekly TRx* LYBALVI Quarterly Net Sales ($M) (Through 12/22/2023) 5,000 $50 4,000 $40 3,000 $30 2,000 $20 1,000 $10 0 $0 1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 By Week 4 Week Rolling Average Week *Source:
Slide 10: LYBALVI: Long-Term, Open-Label Extension Study Builds on Real World Experience
LYBALVI®: Long-Term, Open-Label Extension Study Builds on Real World Experience* Long-term treatment with LYBALVI for up to 4 years highlights its potential as a foundational treatment for appropriate patients with schizophrenia and bipolar I disorder Stability of • Mean change in Clinical Global Im
Slide 11: ARISTADA: LAI for the Treatment of Schizophrenia With Dosing Flexibility
ARISTADA®: LAI for the Treatment of Schizophrenia With Dosing Flexibility • Long-acting injectable (LAI) atypical antipsychotic ARISTADA Annual Net Sales** ($M) indicated for the treatment of schizophrenia in adults • Novel molecular entity designed to address the $324 $350 $302 real-world needs of
Slide 12: VIVITROL: LAI for the Treatment of Alcohol Dependence and Opioid Dependence
VIVITROL®: LAI for the Treatment of Alcohol Dependence and Opioid Dependence • Extended-release opioid antagonist provides VIVITROL Annual Net Sales ($M) therapeutic levels of naltrexone for a one-month period $400 • Indicated for the treatment of alcohol dependence (AD) $450 $380 in patients able t
Slide 13: VUMERITY Offers Long-Term Revenue Growth Opportunity
VUMERITY® Offers Long-Term Revenue Growth Opportunity • Novel oral fumarate for the treatment of relapsing VUMERITY Royalty & Manufacturing Revenue ($M) forms of multiple sclerosis (MS) $128 • Biogen holds exclusive, worldwide license to $140 $115 commercialize $120 $87 • 15% royalty to Alkermes on
Slide 14: Proven Drug Development Capabilities with Advancing Neuroscience Pipeline
Proven Drug Development Capabilities with Advancing Neuroscience Pipeline
Slide 15: Proven Neuroscience Drug Development Capabilities
Proven Neuroscience Drug Development Capabilities Neuroscience drug development expertise has yielded multiple commercial products: Enabled by established capabilities in: Molecular Medicinal Translational Clinical Regulatory Medical Design Chemistry Medicine Development Science Affairs VUMERITY is
Slide 16: Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders
Orexin Dysfunction: Well Defined Opportunity in Narcolepsy and Other Sleep Disorders • In narcolepsy, low orexin levels lead to inconsistent neurotransmitter release, resulting in excessive sleepiness and poor regulation of REM sleep • Narcolepsy (types 1 and 2) affects ~200,000 people in U.S. and 3
Slide 17: OX2R: Molecular Design Challenge and Optimization Parameters
OX2R: Molecular Design Challenge and Optimization Parameters Oral Bioavailability 6 5 4 3 Pharmacokinetic Blood Brain Barrier 2 Properties Penetration 1 0 Selectivity Potency 17 © 2024 Alkermes. All rights reserved.
Slide 18: OX2R: Molecular Design Challenge and Optimization Parameters
OX2R: Molecular Design Challenge and Optimization Parameters Oral Bioavailability ALKS 2680 Investigational oral orexin 2 receptor agonist for the treatment of narcolepsy designed for: Pharmacokinetic Blood Brain Barrier • Improved wakefulness duration and quality Properties Penetration • PK/PD prof
Slide 19: ALKS 2680: Investigational Oral Orexin 2 Receptor Agonist for the Treatment of Narcolepsy
ALKS 2680: Investigational Oral Orexin 2 Receptor Agonist for the Treatment of Narcolepsy ALKS 2680 is a highly potent, selective OX2R agonist Program Status • ≥10 fold more potent than orexin Aa • >5,000-fold selectivity relative to OX1Ra Phase 1b proof-of-concept study underway ✓ Recently comple
Slide 20: ALKS 2680: First-in-Human Data Presented at 2023 World Sleep Meeting
ALKS 2680: First-in-Human Data Presented at 2023 World Sleep Meeting • Single- and multiple- ascending dose study safety and tolerability data (n=80) • Initial proof-of-concept data in patients with Narcolepsy Type 1 (n=4) 20 © 2024 Alkermes. All rights reserved.
Slide 21: ALKS 2680: Results From Full NT1 (n=10) Cohort Support Advancement to Phase 2
ALKS 2680: Results From Full NT1 (n=10) Cohort Support Advancement to Phase 2 Efficacy Safety and Tolerability • Statistically significant and clinically meaningful • Generally well tolerated at all doses tested improvement of maintenance of wakefulness test (MWT) scores at each dose level (1 mg, 3
Slide 22: ALKS 2680: Advancing Into Phase 2 in 2024
ALKS 2680: Advancing Into Phase 2 in 2024 Planned Narcolepsy Type 1 Phase 2 Design 22 © 2024 Alkermes. All rights reserved.
Slide 23: Phase 2 Designed to Capture Standard Endpoints and Exploratory Measures
Phase 2 Designed to Capture Standard Endpoints and Exploratory Measures Planned Primary and Secondary Assessments Key Exploratory Measures • Maintenance of Wakefulness Test (MWT) • Patient reported outcomes ◦ Change from baseline in average sleep latency on ◦ Focused on quality of wakefulness and ov
Slide 24: Building a Neuroscience Development Pipeline That Leverages Alkermes' Capabilities
Building a Neuroscience Development Pipeline That Leverages Alkermes’ Capabilities Orexin 2 pathway activation R&D Framework • Narcolepsy • Other excessive daytime sleepiness disorders • Other neuropsychiatric disorders • Strong biological rationale • Challenging molecular design Other internal neur
Slide 25: Positioned for Sustained Profitability and Significant Cash Generation
Positioned for Sustained Profitability and Significant Cash Generation
Slide 26: Commercial Performance and Efficient Cost Structure Expected to Drive Meaningful Profitability
Commercial Performance and Efficient Cost Structure Expected to Drive Meaningful Profitability 2024 Key Financial Expectations: Revenues • Continued growth of proprietary commercial products revenue Key 2024 Financial Metrics ** • INVEGA SUSTENNA® U.S. royalty expiration in August 2024 Operating Exp
Slide 27: 2024 Strategic Priorities
2024 Strategic Priorities Driven by 4 core products Deliver strong commercial growth and profitability and streamlined operating structure Advance orexin 2 receptor agonist Initiate phase 2 program program Advance internal development candidates and explore Expand neuroscience pipeline external pipe
Slide 28: www.alkermes.com
www.alkermes.com © 2024 Alkermes. All rights reserved.
Alkermes — 42nd Annual J.P. Morgan Healthcare Conference 2024 on 6ix